Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
Verve: Potential To Advance Gene Based Editing Drugs For ASCVD
02:27pm, Monday, 11'th Dec 2023
Verve Therapeutics, Inc. released positive interim data from its phase 1b heart-1 study using VERVE-101 for treating HeFH patients; LDL-C reduced by as much as 55% after a single dose. IND clearance f
Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program
01:19pm, Thursday, 30'th Nov 2023
Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosc
Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect?
11:17am, Monday, 27'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable
Why Verve Therapeutics Stock Crashed as Much as 30% This Week
03:41pm, Friday, 17'th Nov 2023
Two Verve Therapeutics patients suffered heart attacks in a clinical trial. This data may not be as damning as some think.
Verve Therapeutics: Why Great Results Aren't Enough
05:41am, Thursday, 16'th Nov 2023
The first treatment candidate from Verve Therapeutics to begin clinical trials recently produced positive results. Shares of the biotech collapsed despite results that show VERVE-101 can control patie
After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy?
05:20am, Thursday, 16'th Nov 2023
Two patients in one of Verve Therapeutics' clinical trials experienced heart attacks. One of those heart attacks is possibly connected to its gene editing therapy.
These 2 Stocks Are Making Big Monday Moves
12:07pm, Monday, 13'th Nov 2023
Markets opened only slightly lower on Monday morning. Monday.com reported strong financial results and boosted its guidance for the rest of the year.
Verve Therapeutics' stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment
09:01am, Monday, 13'th Nov 2023
Verve Therapeutics Inc. shares VERV, -2.12% fell 40% premarket on Monday after the biotech company on Sunday released early-stage clinical trial data on its experimental gene-editing treatment for hig
2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher
05:57am, Thursday, 09'th Nov 2023
TransMedics Group's transplant organ retrieval and delivery business is accelerating now that it doesn't have to rely on third parties for charter flights. Verve Therapeutics and its partnership with
Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?
08:16am, Wednesday, 01'st Nov 2023
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Inside Cathie Wood's Portfolio: 3 Stocks She Is Betting Millions On
05:40am, Wednesday, 01'st Nov 2023
Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, and millions o
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
07:09pm, Tuesday, 31'st Oct 2023
The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.
With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?
08:30am, Monday, 30'th Oct 2023
The FDA just gave it the go-ahead to test its lead gene-editing program in humans. But the young biotech will still likely need to raise money in a couple of years.
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
09:45am, Tuesday, 10'th Oct 2023
Growth stocks have wilted under an avalanche of macro headwinds in late 2023. This broad sell-off, though, may have created some incredible bargains.
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
09:01am, Wednesday, 27'th Sep 2023
Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
